Literature DB >> 19109479

Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia.

Manuel Cuenca-Estrella1, Yolanda Meije, Carmen Diaz-Pedroche, Alicia Gomez-Lopez, Maria J Buitrago, Leticia Bernal-Martinez, Carlos Grande, Rafael San Juan, Manuel Lizasoain, Juan L Rodriguez-Tudela, Jose M Aguado.   

Abstract

A study was designed to assess the reliability of the serial detection of Aspergillus sp. DNA to diagnose invasive aspergillosis (IA) in patients with febrile neutropenia. Two blood and two serum samples were taken weekly from 83 patients. A total of 2,244 samples were analyzed by real-time quantitative PCR. Twelve (14.4%) patients were diagnosed with IA. Taking two consecutive positive results as the diagnostic criterion, PCR detected 11 cases, with 4 false positives, giving sensitivity, specificity, positive, and negative predictive values of 91.6%, 94.4%, 73.3%, and 98.5%, respectively. On analyzing in conjunction with high-resolution chest tomography (HRCT) and galactomannan (GM) testing, the combination of serial PCR and GM detected 100% of aspergillosis cases, with a positive predictive value of 75.1%. This diagnostic strategy presented, according to CART analysis, a receiver-operator curve with an area under the curve of 0.97 (95% confidence interval, 0.895 to 1.032; P < 0.01), with a relative risk of IA 6.92 times higher than the control population and with predictive success of 95.2%. As regards early diagnosis, the serial detection of Aspergillus DNA took on average 21 days less than HRCT and 68 days less than GM. The serial detection of Aspergillus DNA using real-time quantitative PCR has great diagnostic applicability, which increases when combined with GM quantification.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109479      PMCID: PMC2643681          DOI: 10.1128/JCM.01716-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  27 in total

1.  Radiation cost of helical high-resolution chest CT.

Authors:  David A Leswick; Steve T Webster; Brad A Wilcox; Derek A Fladeland
Journal:  AJR Am J Roentgenol       Date:  2005-03       Impact factor: 3.959

2.  Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go.

Authors:  J Peter Donnelly
Journal:  Clin Infect Dis       Date:  2006-01-17       Impact factor: 9.079

3.  Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases.

Authors:  S Cesaro; C Stenghele; E Calore; E Franchin; I Cerbaro; R Cusinato; G Tridello; R Manganelli; M Carli; G Palù
Journal:  Mycoses       Date:  2008-03-03       Impact factor: 4.377

4.  Role of prospective screening of blood for invasive aspergillosis by polymerase chain reaction in febrile neutropenic recipients of haematopoietic stem cell transplants and patients with acute leukaemia.

Authors:  Catriona Halliday; Rebecca Hoile; Tania Sorrell; Greg James; Satya Yadav; Peter Shaw; Marie Bleakley; Ken Bradstock; Sharon Chen
Journal:  Br J Haematol       Date:  2006-02       Impact factor: 6.998

5.  Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study.

Authors:  Johan Maertens; Koen Theunissen; Gregor Verhoef; Johnny Verschakelen; Katrien Lagrou; Eric Verbeken; Alexander Wilmer; Jan Verhaegen; Marc Boogaerts; Johan Van Eldere
Journal:  Clin Infect Dis       Date:  2005-09-29       Impact factor: 9.079

6.  Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients.

Authors:  Rodrigo Martino; Maricel Subirá; Montserrat Rovira; Carlos Solano; Lourdes Vázquez; Guillermo F Sanz; Alvaro Urbano-Ispizua; Salut Brunet; Rafael De la Cámara
Journal:  Br J Haematol       Date:  2002-02       Impact factor: 6.998

7.  Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay.

Authors:  Kieren A Marr; Michel Laverdiere; Anja Gugel; Wendy Leisenring
Journal:  Clin Infect Dis       Date:  2005-05-05       Impact factor: 9.079

8.  The evolution and evaluation of a whole blood polymerase chain reaction assay for the detection of invasive aspergillosis in hematology patients in a routine clinical setting.

Authors:  P Lewis White; Christopher J Linton; Michael D Perry; Elizabeth M Johnson; Rosemary A Barnes
Journal:  Clin Infect Dis       Date:  2006-01-17       Impact factor: 9.079

9.  Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies.

Authors:  Martine Florent; Sandrine Katsahian; Anne Vekhoff; Vincent Levy; Bernard Rio; Jean-Pierre Marie; Anne Bouvet; Muriel Cornet
Journal:  J Infect Dis       Date:  2006-01-30       Impact factor: 5.226

10.  Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more
  23 in total

1.  Molecular diagnostics for invasive fungal infections: a call for refinement and implementation.

Authors:  Gary W Procop
Journal:  J Mol Diagn       Date:  2009-12-10       Impact factor: 5.568

2.  Advances and prospects for molecular diagnostics of fungal infections.

Authors:  Stéphane Bretagne
Journal:  Curr Infect Dis Rep       Date:  2010-11       Impact factor: 3.725

Review 3.  Updates in Laboratory Diagnostics for Invasive Fungal Infections.

Authors:  David Terrero-Salcedo; Margaret V Powers-Fletcher
Journal:  J Clin Microbiol       Date:  2020-05-26       Impact factor: 5.948

Review 4.  Molecular and nonmolecular diagnostic methods for invasive fungal infections.

Authors:  Marios Arvanitis; Theodora Anagnostou; Beth Burgwyn Fuchs; Angela M Caliendo; Eleftherios Mylonakis
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

5.  Universal antifungal therapy is not needed in persistent febrile neutropenia: a tailored diagnostic and therapeutic approach.

Authors:  Manuela Aguilar-Guisado; Almudena Martín-Peña; Ildefonso Espigado; Maite Ruiz Pérez de Pipaon; José Falantes; Fátima de la Cruz; José M Cisneros
Journal:  Haematologica       Date:  2011-11-04       Impact factor: 9.941

6.  Diagnostic value of PCR analysis of bacteria and fungi from blood in empiric-therapy-resistant febrile neutropenia.

Authors:  Akiko Nakamura; Yuka Sugimoto; Kohshi Ohishi; Yumiko Sugawara; Atsushi Fujieda; Fumihiko Monma; Kei Suzuki; Masahiro Masuya; Kazunori Nakase; Yoshiko Matsushima; Hideo Wada; Naoyuki Katayama; Tsutomu Nobori
Journal:  J Clin Microbiol       Date:  2010-04-14       Impact factor: 5.948

7.  Utility of real-time PCR for detection of Exserohilum rostratum in body and tissue fluids during the multistate outbreak of fungal meningitis and other infections.

Authors:  Lalitha Gade; Dale E Grgurich; Thomas M Kerkering; Mary E Brandt; Anastasia P Litvintseva
Journal:  J Clin Microbiol       Date:  2014-12-17       Impact factor: 5.948

8.  Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients.

Authors:  Jan Springer; C O Morton; Michael Perry; Werner J Heinz; Melinda Paholcsek; Mona Alzheimer; T R Rogers; Rosemary A Barnes; Hermann Einsele; Juergen Loeffler; P Lewis White
Journal:  J Clin Microbiol       Date:  2013-02-20       Impact factor: 5.948

Review 9.  PCR-based diagnosis of human fungal infections.

Authors:  Prasanna D Khot; David N Fredricks
Journal:  Expert Rev Anti Infect Ther       Date:  2009-12       Impact factor: 5.091

Review 10.  Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies.

Authors:  Mary Mansour Riwes; John R Wingard
Journal:  Expert Rev Hematol       Date:  2012-12       Impact factor: 2.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.